Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Type III and VI Collagen Remodeling Biomarkers’ Potential to Distinguish Between IPF and HP
May 17, 2025
Type III and VI collagen remodeling biomarkers have the potential to distinguish
between IPF and HP
Introduction
IPF and HP are two ILDs with similar clinical phenotype but distinct management, making their precise separation critical. Serological biomarkers may assist in this distinction. Extracellular matrix (ECM) remodeling is a hallmark of fibrosis. Collagen formation and degradation processes release peptide fragments into the blood that can be quantified by the nordicPRO-C3™ and nordicPRO-C6™ (type III and VI collagen formation), or the C3M and C6M (type III and VI collagen degradation) assays.
In this study we assessed the clinical value of Type III and VI collagen remodeling biomarkers and their potential to act as a tool to distinguish between HP and IPF in two separate, independent cohorts.
Poster
Conclusion
These findings suggest that ECM remodeling biomarkers such as nordicPRO-C3™ could act as potential tools to distinguish between HP and IPF.
